Elucidation of a human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapy

Simple item page
dc.contributor.authorFitzgerald, Bryna L.en_ZA
dc.contributor.authorIslam, M. Nurulen_ZA
dc.contributor.authorGraham, Barbaraen_ZA
dc.contributor.authorMahapatra, Sebabrataen_ZA
dc.contributor.authorWebb, Kristoforen_ZA
dc.contributor.authorBoom, W. Henryen_ZA
dc.contributor.authorMalherbe, Stephanus T.en_ZA
dc.contributor.authorJoloba, Moses L.en_ZA
dc.contributor.authorJohnson, John L.en_ZA
dc.contributor.authorWinter, Jillen_ZA
dc.contributor.authorWalzl, Gerharden_ZA
dc.contributor.authorBelisle, John T.en_ZA
dc.date.accessioned2021-01-19T07:28:57Z
dc.date.available2021-01-19T07:28:57Z
dc.date.issued2018-12-26
dc.descriptionCITATION: Fitzgerald, B. L., et al. 2019. Elucidation of a human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapy. ACS Infectious Diseases, 5(3):353-364, doi:10.1021/acsinfecdis.8b00241.
dc.descriptionThe original publication is available at https://pubs.acs.org
dc.description.abstractENGLISH ABSTRACT: The evaluation of new tuberculosis (TB) therapies is limited by the paucity of biomarkers to monitor treatment response. Previous work detected an uncharacterized urine metabolite with a molecular mass of 874.3547 Da that showed promise as a biomarker for successful TB treatment. Using mass spectrometry combined with enzymatic digestions, the metabolite was structurally characterized as a seryl-leucine core 1 Oglycosylated peptide (SLC1G) of human origin. Examination of SLC1G in urine revealed a significant abundance increase in individuals with active TB versus their household contacts and healthy controls. Moreover, differential decreases in SLC1G levels were observed by week one in TB patients during successful treatment versus those that failed treatment. The SLC1G levels were also associated with clinical parameters used to measure bacterial burden (GeneXpert) and inflammation (positron emission tomography-computed tomography (PET-CT)). These results demonstrate the importance of metabolite identification and provide strong evidence for applying SLC1G as a biomarker of TB treatment response.en_ZA
dc.description.urihttps://pubs.acs.org/doi/10.1021/acsinfecdis.8b00241
dc.description.versionPublisher's version
dc.format.extent12 pagesen_ZA
dc.identifier.citationFitzgerald, B. L., et al. 2019. Elucidation of a human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapy. ACS Infectious Diseases, 5(3):353-364, doi:10.1021/acsinfecdis.8b00241
dc.identifier.issn2373-8227 (online)
dc.identifier.otherdoi:10.1021/acsinfecdis.8b00241
dc.identifier.urihttp://hdl.handle.net/10019.1/108996
dc.language.isoen_ZAen_ZA
dc.publisherAmerican Chemical Societyen_ZA
dc.rights.holderAmerican Chemical Societyen_ZA
dc.subjectTuberculosisen_ZA
dc.subjectAntitubercular agentsen_ZA
dc.subjectBiochemical markersen_ZA
dc.subjectTherapeutic drug monitoringen_ZA
dc.titleElucidation of a human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapyen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fitzgerald_elucidation_2019.pdf
Size:
1.81 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Molecular Biology and Human Genetics)